



Correction: Fragment-based covalent ligand discovery

Cite this: *RSC Chem. Biol.*, 2021, 2, 670

Wenchao Lu,^{ab} Milka Kostic,^a Tinghu Zhang,^{ab} Jianwei Che,^{abc} Matthew P. Patricelli,^d Lyn H. Jones,^c Edward T. Chouchani^{ae} and Nathanael S. Gray^{*ab}

DOI: 10.1039/d1cb90008k

Correction for 'Fragment-based covalent ligand discovery' by Wenchao Lu *et al.*, *RSC Chem. Biol.*, 2021, DOI: 10.1039/d0cb00222d.

rsc.li/rsc-chembio

The authors regret that an incorrect version of Fig. 2 was included in the original article, where the structure of Sulfofin in Fig. 2D was incorrectly shown. The correct version of Fig. 2 is presented below.



^a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. E-mail: nathanael_gray@dfci.harvard.edu

^b Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA

^c Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, MA 02215, USA

^d Vividion Therapeutics, La Jolla, CA 92121, USA

^e Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA




Fig. 2 The structures of representative well-characterized electrophilic fragments identified from target-based screening strategies in recent years. (A) KRAS-G12C allele-specific covalent fragment (6H05) identified from tethering screen, which was further elaborated to compound 12.³¹ This inspired numerous groups to develop further optimized inhibitors, within which AMG510³⁵ and MRTX849³⁶ successfully entered clinical trials. (B) Compound 5 targets the active cysteine (C885) of HOIP.³⁷ (C) OTUB2-COV-1 targets the active cysteine (C51) of OTUB2 and NUDT7-COV-1 target C73 of NUDT7.³⁸ (D) Sulfopin targets the active cysteine of Pin1 (C113).³⁹ (E) Representative covalent fragment scaffolds target the active cysteine (C145) of SARS-COV-2 main protease (Mpro).⁴⁰

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

